Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SRPT Sarepta Therapeutics
120.860-2.030-1.65%
Close
01/30 16:00 ET
High
123.000
Open
122.690
Turnover
72.95M
Low
120.720
Pre Close
122.890
Volume
601.37K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Resmed (RMD) and Sarepta Therapeutics (SRPT)
Raymond James & Associates Sells 10,648 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Raymond James & Associates lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 42.9% in the 3rd quarter, according to its most recent disclosure with the SEC. Th
Brinker Capital Investments LLC Acquires 150 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Brinker Capital Investments LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 3.6% during the third quarter, according to the company in its most recent 13F filing
SVB Leerink Reiterates Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Rating)'s stock had its "outperform" rating reaffirmed by stock analysts at SVB Leerink in a research note issued on Friday, Benzinga reports. They presently h
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and 2seventy Bio (TSVT)
9 Analysts Have This to Say About Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings52200Last 30D010001M
Sarepta Therapeutics Price Target Maintained With a $160.00/Share by SVB Leerink
Sarepta Therapeutics Price Target Maintained With a $160.00/Share by SVB Leerink
SVB Leerink Reiterates Outperform on Sarepta Therapeutics, Maintains $160 Price Target
SVB Leerink analyst Joseph Schwartz reiterates Sarepta Therapeutics with a Outperform and maintains $160 price target.
Connecticut Wealth Management LLC Invests $223,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Connecticut Wealth Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) in the 3rd quarter, according to the company in its most recent filing with
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shift From Loss To Profit
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Sarepta Therapeutics, Inc., a commercial-sta
Company Overview
More
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
CEO： --
Market： NASDAQ
Listing Date： 06/04/1997
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet